Drug intelligence / Profile preview

HAMg

Development stage: Preclinical
Lead developer: RuenHuei
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics

Overview

HAMg is a recombinant protein influenza vaccine candidate developed by RH Biopharma (RH Group). The vaccine utilizes a monoglycosylated hemagglutinin (HA) technology platform designed to create a broadly protective, potentially universal flu vaccine. By reducing the glycan shield on the HA protein to a single sugar residue (monoglycosylation), the vaccine exposes conserved epitopes that are typically masked by complex glycans. This exposure allows the immune system to generate antibodies that recognize a wide range of influenza strains and subtypes, providing cross-protective immunity. HAMg is currently in the preclinical stage of development.

Other names: Monoglycosylated Hemagglutinin flu vaccineRH Group-Influenza hemagglutinin (HA)-vaccine (recombinant protein)-influenza

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on HAMg.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HAMg.

Explore the full profile